January 2, 2025) - A Race Against Blindness, an Arizona-based nonprofit organization, has awarded a $1 million grant to fund research and clinical trials focused on Bardet-Biedl Syndrome 1 (BBS1 ...

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with setmelanotide.

Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor agonist that the FDA previously approved for chronic weight management in people with Bardet-Biedl syndrome in 2022 ...

Opens in a new tab or window The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with syndromic or monogenic obesity due to Bardet-Biedl syndrome ...

The Food and Drug Administration (FDA) has expanded the approval of Imcivree ® (setmelanotide) to include children as young as 2 years old with obesity due to Bardet-Biedl syndrome (BBS ...